FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

washington,	D.C.	20549	

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PERRIN MARK D					2. Issuer Name and Ticker or Trading Symbol INVIVO THERAPEUTICS HOLDINGS								(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
TEITH	TVIII II CI V	<u> </u>			<u> CC</u>	ORP	. NVIV	1					X	Director			10% Owi	ner	
(Last)	(F	rst) (I	Middle)										X	Officer (give title		Other (sp below)	pecify	
C/O INVIVO THERAPEUTICS HOLDINGS CORP.				ORP.	3. Date of Earliest Transaction (Month/Day/Year) 01/18/2017							CHIEF EXECUTIVE OFFICER							
ONE KEN	DALL SC	UARE, SUITE E	314402		01/	10/2	017												
					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street)													Line)	file	ad bu On a	Damas	tina Davasa		
CAMBRII	OGE M	A 0	2139										X		•		ting Person One Reporti	ng	
,														Person	su by Mon	e man	One Reporti	ig	
(City)	(S	tate) (2	Zip)																
		Tal	ole I - Non	-Deriv	ativ	e Se	curities	Acc	quired,	Dis	posed of	f, or Ber	eficially	Owned					
Date				n/Day/Year) it		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr.		ies Acquire Of (D) (Inst	d (A) or r. 3, 4 and 5)	Beneficial Owned Fo	Forn ly (D) o	Form:	: Direct Ir Indirect B str. 4) C	. Nature of ndirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price	Reported Transaction (Instr. 3 ar			"	nstr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 2. Conversion Date (Month/Day/Year) 3. Transaction Date Execution Date (Month/Day/Year) 6. Conversion Date (Month/Day/Year) 7. Conversion Date (Month/Day/Year)		ate, Ti	4. Transaction Code (Instr. 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Followin Reported	e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
			c	Code V (A)		(D)			Expiration Date	Title	Amount or Number of Shares		Transac (Instr. 4)						
Stock Option(Right to Buy)	\$4.35	01/18/2017			A		320,000		(1)		01/18/2027	Common Stock	320,000	\$0	320,0	00	D		

Explanation of Responses:

1. This option vests as to 25% of the shares on the first anniversary of the date of grant, and the remaining shares vest thereafter on a monthly basis in 36 equal monthly installments.

01/20/2017 /s/ Mark D. Perrin

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.